Posts Tagged ‘nasdaq’

Sirius XM Radio, Inc. (SIRI) – Buzz Stock of the Day

Monday, October 4th, 2010

Shares of satellite radio service provider, Sirius XM Radio, Inc. (Nasdaq: SIRI) were up more than 2 percent from Friday’s closing price, in morning trading on Monday after the company announced that it expects to end the year with 20.1 million subscribers. Sirius ended fiscal 2009 with 18.8 million subscribers.

“I think it’s a combination of more cars being sold, I think they had a pretty conservative outlook generally, I think they’re penetrating the used market better than we thought,” said David Bank, Managing Director of RBC Capital Markets, in a recent CNBC interview.

Miller Tabek analyst David Joyce recently downgraded Sirius XM from BUY to NEUTRAL, citing valuation concerns, but maintained his short-term price target of $1.25 and long-term price target of $1.45. Joyce upgraded Sirius XM to BUY on July 7th in response to the company’s pre-announced Q2 subscriber metrics. Noting that SIRI was now currently trading about 6% away from his short-term $1.25 price target, and that the stock has increased 24% in just the past three months and 98% year-to-date.

“It is not that we just had a revelation that SIRI is more expensive than traditional media companies, but we wish to maintain discipline with our price targets,” Joyce said.
[–quote–]
SIRI is currently trading at about 13.7x Joyce’s 2011E OIBDA (Operating Income Before Depreciation and Amortization) estimate of $752 million, which he still views as an attractive 0.6x PEG (Price/Earnings To Growth) ratio based on his 22% long-term OIBDA CAGR (Compound Annual Growth Rate) estimate, but at 53x 2010 estimated FCF (Free Cash Flow) Joyce sees Sirius XM’s valuation “far above other subscription-model companies in our universe.” Joyce noted that subscription-based cable operators were currently at an average of 5.6x 2011 estimated OIBDA multiple and an average 10.1x 2010 estimated FCF. Joyce also noted that SIRI was trading at about 27x his 2011 estimated operating income estimate of $380 million, which he pointed out was also far above the 10.8x 2011 estimated Operating Income average and the 14.4x 2010 estimated FCF average among other entertainment companies that Miller Tabek follows, which have mixed subscription, advertising, and content business models.

Last Thursday, Standard and Poor’s announced that it was upgrading Sirius XM to a “B” corporate credit rating for the company on CreditWatch with positive implications. Prior to this, its rating was “B.”

“The positive CreditWatch listing reflects the company’s prospects for continued improvement in operating performance and declining debt leverage for the remainder of 2010, which could lead to a rating upgrade,” a press release stated. S&P also mentioned the Howard Stern contract, stating that “the company’s five-year agreement with radio talk show host Howard Stern expires on Dec. 31, 2010. Despite onerous contract costs, Stern has been important to the growth of the service due to his loyal fan base and exclusive content, which is not available on terrestrial radio. We believe that subscriber churn would increase, potentially dramatically, should he decide not to renew his contract.”

Opexa Therapeutics Inc (Nasdaq: OPXA) Buzz Stock of the Day

Tuesday, September 14th, 2010

Opexa TherapeuticsWe originally covered Opexa Therapeutics in September of 09, today Opexa (Nasdaq: OPXA) shares surged as much as 23.4%  to a high of $1.95 ahead of the stem cell research firm’s presentation this afternoon at the Rodman & Renshaw healthcare conference. Neil K. Warma, Opexa’s President and Chief Executive Officer will deliver a corporate presentation that will include an overview of the Company’s ongoing clinical development program for Tovaxin, the Company’s lead therapy for Multiple Sclerosis (MS).

In addition to Opexa’s corporate presentation, other contributing factors are at play in the Company’s surging share prices. Vista Partners, a research and consulting firm, announced Monday that it has initiated coverage on Opexa Therapeutics with a twelve month target price of $4.40, representing a 300% premium to Friday’s closing value.
[–quote–]
Ross Silver, Principal Analyst at Vista Partners stated, “Opexa’s lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, has shown promising clinical data to date.” Silver went on to address Opexa’s stem cell therapy partnership with Novartis (NYSE: NVS) stating that approval of other autologous cellular immunotherapy treatments, most notably Dendreon’s Provenge, has increased knowledge and acceptance of stem cell therapies and would “likely increase Opexa’s value amongst potential partners.”

Lastly, ongoing court battles over federally funded stem cell research have been affecting the Stem Cell Stocks Index, which is trading down -2.5% for the past 30 days. At the end of last month, all 11 of the Stem Cell Stocks Index components are -30% from their 52-week high with Opexa Therapeutics more than -60% from its peak.

SinoCoking and Coke Chemical Industries, Inc. (SCOK) – Buzz Stock of the Day

Monday, August 23rd, 2010

Shares of coal products maker SinoCoking and Coke Chemical Industries, Inc. (Nasdaq: SCOK) were up nearly 30 percent from Friday’s closing price in morning trading on Monday.

Last week, the company announced that its wholly controlled affiliate, Pingdingshan Hongli Coal & Coke Co., Ltd. entered into a definitive agreement to acquire a 60 percent equity interest in Baofeng Shuangrui Coal Co., Ltd. for approximately $12.4 million. Baofeng operates the Xingsheng Coal Mine. The coalmines are similar in size, each with 2 million metric tons of estimated coal reserves.
[–quote–]
“This is a significant milestone and denotes the first step in our consolidation strategy,” said Jianhua Lv, Chairman and CEO of SinoCoking in a statement. “As the Chinese government continues its efforts to consolidate small coal mines to improve both production efficiencies and safety protocols, we are well positioned with the appropriate approvals to capitalize on this opportunity.”

Pursuant to the Agreements, Hongli will the pay the owners of each mining company an aggregate purchase price of $6.2 million in cash, of which approximately $1.5 million was provided as a refundable deposit to examine the financials, licenses, and reserve data. The purchase will be made under the following schedule for each mining company: $1.7 million within 30 business days from the September 10, 2010; $0.7 million within 20 business days from the completion of the transfer of equity interests to Hongli; $0.7 million within six months from the completion of the transfer of equity interests to Hongli; the balance within one year from the completion of the transfer of equity interests to Hongli. If total annual output is less than 150,000 metric tons, Hongli is entitled to an additional 10 percent of equity interests; and if coal reserves are less than 2 million metric tons, Hongli is entitled to an additional 10 percent of equity interests.

Shares of SinoCoking and Coke Chemical Industries, Inc. are trading about 70 percent lower than their 52-week high of $53.70 per share.

Pacific Ethanol, Inc. (PEIX) – Buzz Stock of the Day

Tuesday, August 17th, 2010

We first covered Pacific Ethanol, Inc. (Nasdaq: PEIX) on June 30, 2010, after the company announced that four of its wholly-owned subsidiaries had emerged from bankruptcy. Shares were up almost 60 percent on that day, from the previous day’s closing price.

Shares of Pacific Ethanol surged again on Tuesday, this time as much as 42 percent from the previous day’s closing price after the company posted earnings of $107.8 million or $1.43 per share for the three months ended June 30, compared to a loss of $28.2 million or 49 cents per share in the same period last year. The boost in earnings was primarily due a non-cash gain of $119 million, and an 88 percent increase in total gallons sold, offset by a  lower average price per gallon.
[–quote–]
Net sales in the quarter increased 9 percent to $76.8 million, compared to $70.1 million in the same quarter a year ago. The company also reduced its SG&A expenses by 49 percent, and improved adjusted EBITDA by $8.4 million, compared to the second quarter of 2009.

Pacific Ethanol’s CEO Neil Koehler described the second quarter as “pivotal” for the company. “We delivered sales growth, dramatically reduced operating expenses, and improved adjusted EBITDA,” he said in a statement. “We successfully led the production facilities out of bankruptcy effective June 29th, substantially reducing our debt and other liabilities by $295 million. During the quarter, we also reduced other debt by $9 million. In addition to strengthening our balance sheet, we reduced selling, general and administrative expenses to less than half of what they were for the same quarter last year, thus establishing a stable platform for growth.”

On June 29, 2010, PEI’s wholly-owned plant holding company, PEH, and its four plant subsidiaries exited bankruptcy and the ownership of PEH was transferred to certain lenders. As a result, PEI recorded a $119.4 million non-cash gain from the disposition of liabilities of $294.5 million net of assets of $175.1 million that were removed from its balance sheet. Simultaneously, PEI began operating under its newly announced operating and marketing agreements with the ethanol production facilities upon their emergence from bankruptcy.

ResCare, Inc. (RSCR) – Buzz Stock of the Day

Monday, August 16th, 2010

Shares of home care services provider ResCare, Inc. (Nasdaq: RSCR) surged as much as 20 percent from Friday’s closing price in morning trading on Monday after it was announced that Toronto-based investment firm, Onex offered to buy approximately 75 percent of the common and preferred shares of Res-Care for $12.60 per share, which is a 24 percent premium over Friday’s closing price of $10.14 per share.

Affiliates of Onex currently hold 24.9 percent of the common and preferred shares of Louisville-based Res-Care.
[–quote–]
There currently are about 29 million shares outstanding.

ResCare recently reported second quarter profit of $8.1 million, or 28 cents per diluted common share, up from $7.1 million, or 25 cents per diluted common share in the same period a year ago. Second quarter revenue dipped 2 percent to $396.1 million, compared to revenue of $405.3 million for the same period in 2009. EBITDA for the second quarter of 2010 was $26.4 million versus $23.7 million in the prior year quarter.

ResCare confirmed its 2010 guidance issued on March 8, 2010, including revenues of approximately $1.6 billion and diluted earnings per common share in the range of $1.05 to $1.15.